Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
NovaBay Pharmaceuticals, Inc.
Type
Public
Traded as NYSE MKT: NBY
Industry Health care
Biotechnology
Founded 2000
Founder Ron Najafi
Headquarters Emeryville, California, United States
Key people
Ron Najafi, Ph.D., CEO
Tom Paulson, M.B.A., CFO
Keith R. Bley, Ph.D., Sr. VP of Product Development
Russell Hoon, Sr. VP of Advanced Wound Care
David Stroman, Ph.D., Sr. VP, Ophthalmology
Roy Wu, M.B.A., Sr. VP, Business Development
Glenn Moro,VP, Sales and Marketing Avenova
Number of employees
26 (2013)
Website novabay.com

NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on developing novel, fast-acting, synthetic anti-infectives compounds. These compounds are designed to mimic the body's defense system against infection. The company is currently focused on products for the eye care market. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis

Investment goal date:
Dividends reinvested
NovaBay Pharmaceuticals, Inc. NBY report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-03-19
--
--
Q3 2017
2017-11-08
--
--
Q2 2017
2017-08-10
-0.1100
-0.1100
Q1 2017
2017-05-11
-0.2600
-0.2600
Q4 2016
2017-03-23
-0.1100
-0.1300
Q3 2016
2016-11-10
-0.3400
-0.3400
Q2 2016
2016-08-11
-0.3600
-0.3600
Q1 2016
2016-05-12
-1.2400
-1.2400
Q4 2015
2016-03-03
-1.2600
-1.2600
Q3 2015
2015-11-16
-1.7500
-1.7500
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BANK OF AMERICA CORP /DE/
78356
BlackRock Fund Advisors
657
BlackRock Inc.
657
Creative Planning
192
GOLDMAN SACHS GROUP INC
17276
MetLife Securities, Inc
24
MORGAN STANLEY
6209
NEW ENGLAND SECURITIES CORP /MA/
600
RENAISSANCE TECHNOLOGIES LLC
11024
UBS Group AG
2777
Vanguard Group, Inc
26561
Walleye Trading LLC
1500
Major Shareholders
Name Relationship
Total Shares
Holding stocks
SIECZKAREK MARK M
1.4100% (715498)
NBY / SLTM /
WU ROY J
0.0400% (19296)
NBY /
PAULSON THOMAS J
0.2800% (142196)
NBY /
Freiman Paul E.
0.0900% (45137)
NBY /
Tufts Robert R.
0.6900% (348408)
NBY /
Dailley Anthony
0.5600% (285259)
NBY /
Najafi Ramin
0.0200% (12000)
NBY /
Stroman David W.
0.0500% (23000)
NBY /
Pioneer Pharma (Singapore) Pte. Ltd.
7.2800% (3698219)
NBY /
NAQU AREA PIONEER PHARMA CO., LTD.
3.9400% (2000000)
NBY /
China Pioneer Pharma Holdings Ltd
1.2000% (608156)
NBY /
Pioneer Pharma (Hong Kong) Co Ltd
13.8000% (7005656)
NBY /
% ()